Bristol Myers Squibb adding 3 medications on TrumpRx

Core Insights - Bristol Myers Squibb is launching three medications on TrumpRx.gov with discounts ranging from 40% to 90% off retail prices [1] - The drug Sotyktu, used for treating moderate-to-severe plaque psoriasis, will be available for $743, a 90% discount from its retail price of $7,135.55 [1] - Zeposia, for relapsing forms of multiple sclerosis, will be offered at a discount between 88% and 90% [4] - Orencia SC, a weekly injection for moderate-to-severe rheumatoid arthritis, will see a 40% price reduction [5] - The initiative is part of ongoing efforts by the White House to reduce healthcare costs amid pressure from the Trump administration [5][11] Company and Industry Developments - Bristol Myers Squibb's new offerings follow the addition of Amgen and GSK to the list of companies providing discounts on TrumpRx.gov [7] - Amgen's medications will be available at an 80% discount, with Amjevita priced at $299 from an original price of $1,484 [8] - Other Amgen drugs, Aimovig and Repatha, will have discounts of 62%, while GSK's Incruse will be discounted by 55% [10] - The White House continues to push for more pharmaceutical companies to join the initiative as Americans seek ways to lower medical costs [11] - Data indicates that under the Biden administration, prescription drug costs increased by 10.4% from January 2021 to January 2025, contrasting with a mere 0.2% increase during the Trump administration [12]